Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

Amneal (NASDAQ:AMRX) launched bimatoprost ophthalmic solution 0.01% on April 9, 2026 in 2.5 mL, 5 mL and 7.5 mL sizes.

Rhea-AI Summary

Amneal (NASDAQ:AMRX) launched bimatoprost ophthalmic solution 0.01% on April 9, 2026 in 2.5 mL, 5 mL and 7.5 mL sizes. The product is the generic equivalent of LUMIGAN and is indicated to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension.

Amneal said the launch supports its Affordable Medicines segment and cites IQVIA U.S. annual sales of approximately $719 million for the 12 months ended February 2026.

Positive

• IQVIA sales ~$719M (12 months ended Feb 2026)
• Launch in three container sizes (2.5mL, 5mL, 7.5mL)
• Targeted growth driver for Affordable Medicines segment

Negative

• Most common adverse reaction: conjunctival hyperemia

Argus Apr 9 session

+0.71% close to close Open Argus

Details

News Market Reaction – AMRX

On Apr 9, the day this news came out, AMRX closed 0.71% above the previous close.

Data tracked by StockTitan Argus for the Apr 9 session.

Key Figures

Bimatoprost strength: 0.01% Bottle size: 2.5 mL Bottle size: 5 mL +2 more

Bimatoprost strength

0.01%

Concentration of ophthalmic solution

Bottle size

2.5 mL

Product presentation volume

Bottle size

5 mL

Product presentation volume

Bottle size

7.5 mL

Product presentation volume

U.S. annual sales

$719 million

IQVIA U.S. sales for bimatoprost 0.01% for 12 months ended Feb 2026

Historical Context

5 past events · Latest: Apr 07

5 events

1. Apr 07

   Patient access donation

   24h Move

   -0.2%

   Announced $2 million donation supporting Parkinson’s patient assistance foundations.

2. Mar 05

   Investor conference

   24h Move

   -0.1%

   Outlined participation in a major healthcare conference with webcast access for investors.

3. Feb 27

   Earnings and guidance

   24h Move

   -4.7%

   Reported $814M Q4 revenue, $3.02B 2025 revenue and issued 2026 growth guidance.

4. Jan 28

   Index inclusion

   24h Move

   +1.1%

   Announced addition to the S&P SmallCap 600 Index effective January 30, 2026.

5. Jan 27

   Earnings date set

   24h Move

   +1.9%

   Scheduled Q4 and full-year 2025 results release and webcast for February 27, 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bimatoprost, ophthalmic, prostaglandin analog, open-angle glaucoma, +2 more

6 terms

bimatoprost medical

"announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL..."

Bimatoprost is a prescription medicine applied to the eye to reduce high pressure inside the eye (used for glaucoma) and to promote eyelash growth; think of it like opening a narrow drain to relieve built-up pressure while also acting as a conditioner that thickens lashes. Investors care because approvals, safety, patent protection and sales performance determine how much revenue the drug can generate and can materially affect a drugmaker’s financial outlook.

ophthalmic medical

"Important ophthalmic treatment expected to be an important growth driver..."

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

prostaglandin analog medical

"Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated..."

A prostaglandin analog is a lab-made drug that mimics natural signaling molecules to change how tissues behave; most commonly it helps drain fluid from the eye to lower internal eye pressure used in treating glaucoma. Investors care because these drugs are often chronic therapies with predictable sales, subject to patent, regulatory approval, and competitive pressures—factors that affect revenue, pricing power, and long-term value in pharmaceutical portfolios.

open-angle glaucoma medical

"pressure in patients with open-angle glaucoma or ocular hypertension."

A common, chronic eye disease in which fluid drains less efficiently from the eye, causing pressure to build and slowly damage the optic nerve; left untreated it typically produces gradual loss of peripheral vision. For investors, it matters because the condition drives demand for medications, surgical devices and diagnostic tests, influences regulatory approvals and reimbursement decisions, and affects long-term market size much like a steadily growing need for maintenance in an aging system.

ocular hypertension medical

"pressure in patients with open-angle glaucoma or ocular hypertension."

Ocular hypertension is when the fluid pressure inside the eye is higher than normal without current damage to the optic nerve or measurable vision loss; think of it like high water pressure in a pipe that increases the chance of future leaks. It matters to investors because it represents a large at‑risk patient group and a potential market for drugs, eye drops, diagnostic tools and procedures aimed at lowering pressure and preventing progression to glaucoma.

conjunctival hyperemia medical

"The most common adverse reaction associated with bimatoprost... is conjunctival hyperemia."

Conjunctival hyperemia is the medical term for visible redness of the white part of the eye caused by increased blood flow in the eye’s surface vessels, similar to how skin can flush when irritated. For investors, it matters because it’s a common side effect tracked in clinical trials and product safety reports—frequent or severe cases can affect a drug or device’s regulatory approval, labeling, patient acceptance and ultimately market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment

BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN^® (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company.

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

“We are pleased to bring another key ophthalmic therapy to our Affordable Medicines portfolio,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “As glaucoma prevalence continues to rise, particularly among the aging population, expanding access to effective treatments like bimatoprost is critical. This launch builds on our strong cadence of complex product introductions and represents an important growth driver for our Affordable Medicines segment.”

The most common adverse reaction associated with bimatoprost ophthalmic solution 0.01% is conjunctival hyperemia. For prescribing information, see package insert here.

According to IQVIA^® U.S. annual sales for bimatoprost ophthalmic solution 0.01% for the 12 months ended February 2026 were approximately $719 million.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more, please visit www.amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amneal (AMRX) announce on April 9, 2026 about bimatoprost 0.01%?

Amneal announced the launch of bimatoprost ophthalmic solution 0.01% in three sizes. According to the company, the product is the generic equivalent of LUMIGAN and will be sold in 2.5 mL, 5 mL and 7.5 mL formats.

How large is the U.S. market for bimatoprost 0.01% cited by Amneal (AMRX)?

The company cited U.S. annual sales of about $719 million for 12 months ended February 2026. According to Amneal, this figure comes from IQVIA and frames the product's commercial opportunity.

What indication does Amneal's bimatoprost ophthalmic solution 0.01% have for patients?

The product is indicated to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension. According to Amneal, it is a prostaglandin analog matching the approved LUMIGAN indication.

What side effects should investors note about Amneal's bimatoprost 0.01% (AMRX)?

The most common adverse reaction is conjunctival hyperemia, which may affect tolerability. According to the company, prescribing information and the package insert list safety and usage details.

How does the bimatoprost launch affect Amneal's Affordable Medicines segment (AMRX)?

Amneal described the launch as an important growth driver for its Affordable Medicines segment. According to the company, the product builds on its cadence of complex product introductions and expands ophthalmic offerings.